The well-known immune checkpoints inhibitors (ICIs) targeting the programmed cell death 1 (PD-1) or the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) checkpoints have demonstrated the potential for relatively tumor-specific immune disinhibition. The gene discussed is CTLA4; the disease is neoplasm.